Amgen's most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $230.00 short put and a strike $225.00 long put offers a potential 30.55% return on risk over the next 14 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $230.00 by expiration. The full premium credit of $1.17 would be kept by the premium seller. The risk of $3.83 would be incurred if the stock dropped below the $225.00 long put strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.
The RSI indicator is above 80 which suggests that the stock is in overbought territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Hanging On: Stocks Catch Support
Tue, 03 Dec 2019 23:57:41 +0000
Mid-cap and small-cap stocks outperform large caps as markets hit support. Can investors glean insight from Amgen's performance?
Pharmacy benefits manager Abarca inks discount deal for Amgen's Enbrel
Tue, 03 Dec 2019 19:01:01 +0000
Abarca, a small Puerto Rico-based pharmacy benefits manager, said on Tuesday Amgen Inc had agreed to give its health insurer clients an additional discount on its blockbuster rheumatoid arthritis drug Enbrel, if patients discontinue taking it after three months. Pharmacy benefits managers like Abarca act as middlemen in the drug supply chain, and negotiate discounts on drugs on behalf of health insurers. Depending on the discounts drugmakers are willing to provide, pharmacy benefits managers make decisions about which drugs to include in coverage plans.
Cramer Weighs In On Biogen, Caterpillar And More
Tue, 03 Dec 2019 16:22:46 +0000
Jim Cramer spoke on CNBC's “Mad Money Lightning Round” about Biogen Inc (NASDAQ: BIIB ). He is concerned about the stock because a Baird analyst expressed his skepticism about Biogen's Alzheimer's …
Biogen's Shares Down on Rating Downgrade by Baird Analyst
Tue, 03 Dec 2019 14:29:02 +0000
Biogen's (BIIB) shares decline following a rating downgrade by an analyst at Robert W. Baird on concerns related to approval of Alzheimer's disease candidate, aducanumab.
Where to Buy Booming Biotech ETFs
Tue, 03 Dec 2019 14:26:27 +0000
Discover why biotech stocks are surging despite large fund outflows. Monitor these three industry ETFs for "buy the dip" opportunities.
Also on Market Tamer…
Follow Us on Facebook